Ardelyx, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ

20 Feb 2025

ARDX

10-K: Ardelyx Reports Strong Revenue Growth for 2024, Navigates Challenges in Changing Healthcare Landscape

Ardelyx reports significant revenue growth driven by IBSRELA and XPHOZAH sales, while addressing challenges related to Medicare Part D coverage changes for XPHOZAH.

NASDAQ

22 Feb 2024

ARDX

Ardelyx, INC

10-K: Ardelyx Reports Full Year 2023 Results, Highlights Commercial Growth and Strategic Advances

Ardelyx's 2023 10-K filing details a year of commercial expansion with IBSRELA and the launch of XPHOZAH, alongside ongoing financial challenges and strategic developments.